A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Phase 3 – large-scale trial before approval
Conditions:
Major Depressive Disorder
Sponsor: Xenon Pharmaceuticals Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline in the SHAPS score at Week 6, Change from baseline in the HAMD-17 score at Week 1, Change from baseline in the CGI-S score at Week 6
Change from baseline in the HAMD-17 score at Week 6.
Description
Change from baseline in the SHAPS score at Week 6, Change from baseline in the HAMD-17 score at Week 1, Change from baseline in the CGI-S score at Week 6
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 140 participants
БГ